WO2023135198 - HUMAN NTCP BINDERS FOR THERAPEUTIC USE AND LIVER-SPECIFIC TARGETED DELIVERY
National phase entry:
Publication Number
WO/2023/135198
Publication Date
20.07.2023
International Application No.
PCT/EP2023/050615
International Filing Date
12.01.2023
Title **
[English]
HUMAN NTCP BINDERS FOR THERAPEUTIC USE AND LIVER-SPECIFIC TARGETED DELIVERY
[French]
LIANTS NTCP HUMAINS POUR UTILISATION THÉRAPEUTIQUE ET ADMINISTRATION CIBLÉE SPÉCIFIQUE AU FOIE
Applicants **
VIB VZW
Suzanne Tassierstraat 1
9052 Gent, BE
VRIJE UNIVERSITEIT BRUSSEL
Pleinlaan 2
1050 Brussel, BE
INSTITUT PASTEUR
25 - 28 Rue du Docteur Roux
75724 Paris Cedex 15, FR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
3, rue Michel-Ange
75794 Paris Cedex 16, FR
Inventors
STEYAERT, Jan
Beukenbosstraat 108
1652 Beersel, BE
PARDON, Els
Hertogstraat 4
3111 Wezemaal, BE
REYES, Nicolas
Institut European de Chimie et Biologie
2 Rue Robert Escarpit
33607 Pessac, FR
GOUTAM, Kapil
Institut European de Chimie et Biologie
2 Rue Robert Escarpit
33607 Pessac, FR
IELASI, Francesco Simone
Institute for Advanced Biosciences (IAB)
INSERM U1209 / CNRS UMR5309
Université Grenoble Alpes
38700 Grenoble, FR
Priority Data
22151078.7
12.01.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1556 | |
| EPO | Filing, Examination | 5876 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3310 |
Total: 11911 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The disclosure relates to binding agents and compositions specifically binding the human Na+-taurocholate co-transporting polypeptide (NTCP/ SLC10A1), thereby stabilizing a NTCP conformational state which allosterically inhibits its bile salt transport function. More specifically, the disclosure discloses Nanobodies that lock an inward-facing or open-pore NTCP conformational state, thereby useful as novel hepatitis virus B (HBV) and/or hepatitis virus D (HDV) antiviral, for treatment of liver disease, or as vehicle for targeted-delivery to the liver. Finally, the disclosure relates to a screening assay wherein said Nanobodies are used as a tool to identify NTCP conformation-selective compounds with therapeutic potential.[French]
La divulgation concerne des agents de liaison et des compositions se liant de manière spécifique au polypeptide co-transportant du Na+-taurocholate humain (NTCP/SLC10A1), stabilisant ainsi un état conformationnel de NTCP qui inhibe de manière allostérique sa fonction de transport de sel biliaire. Plus particulièrement, la divulgation concerne des nanocorps qui verrouillent un état conformationnel NTCP orienté vers l'intérieur ou à pores ouverts, ce qui est utile en tant que nouvel antiviral contre le virus de l'hépatite B (HBV) et/ou le virus de l'hépatite D (HDV), pour traiter une maladie hépatique, ou en tant que véhicule pour une administration ciblée au foie. Enfin, la divulgation concerne un essai de criblage, lesdits nanocorps étant utilisés en tant qu'outil pour identifier des composés sélectifs de conformation NTCP ayant un potentiel thérapeutique.